Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03930641

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Neovascular Age Related Macular Degeneration Clinical Trial

Official title:
An Open-Label, Single-Arm, Multicenter, Phase IIIb Study in Patients With Neovascular Age-Related Macular Degeneration to Evaluate the Safety of Brolucizumab 6 mg in Prefilled Syringe

Clinical Trial Summary

This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations of the prefilled syringe use for intravitreal injection.

Clinical Trial Description

The primary objective of this study was to evaluate the safety of brolucizumab 6 mg delivered in a pre-filled syringe (PFS) in subjects with neovascular age-related macular degeneration (nAMD) with the primary endpoint being the incidence of ocular and non-ocular adverse events (AEs). There were no other objectives for this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03930641
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date May 23, 2019
Completion date July 2, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02251366 - NVAMD Satellite Study N/A
Unknown status NCT00767949 - Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration Phase 1
Completed NCT00764738 - Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration Phase 2/Phase 3
Completed NCT00383370 - Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD Phase 1
Completed NCT01678963 - Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD) Phase 2
Completed NCT01863199 - Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) Phase 4
Recruiting NCT05562947 - A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration Phase 3
Completed NCT04239027 - A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration Phase 3
Completed NCT00574093 - Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD Phase 2
Completed NCT00685100 - Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone Phase 3
Completed NCT01942213 - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. N/A
Recruiting NCT00640640 - The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD) N/A